Breeze Holdings Acquisition Corp. shareholders approved the business combination with YD Biopharma Limited.
The combined company will operate as YD Bio Limited and trade on Nasdaq under the ticker symbol 'YDES'.
The closing of the transaction is expected to occur within the next two weeks.
Approval of Business Combination
Stockholders voted in favor of the business combination with 3,127,474 shares, with only 1,000 shares against and 21 abstentions.
Trading on Nasdaq
Upon closing, the combined company's ordinary shares will begin trading on the Nasdaq Stock Market under the ticker symbol 'YDES'.
Advisors
ArentFox Schiff LLP is the legal advisor to YD Biopharma, I-Bankers Securities, Inc. is the financial advisor to Breeze, Woolery & Co. PLLC is the legal advisor to Breeze, and Ogier is the Cayman Islands legal advisor to Breeze.
- The approval of the business combination sets the stage for the combined company's operations as YD Bio Limited.
- Trading on the Nasdaq under the new ticker symbol 'YDES' will enhance the company's visibility and access to a broader investor base.
The successful approval of the business combination between Breeze Holdings Acquisition Corp. and YD Biopharma Limited marks a significant milestone in the companies' journey towards creating a leading biopharmaceutical entity.